Feb 11, 2021 / 09:30PM GMT
Operator
Good afternoon, ladies and gentlemen, and welcome to the Amicus Therapeutics' conference call and webcast. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Head of Investor Relations. You may begin.
Andrew Faughnan - Amicus Therapeutics, Inc. - Director of IR
Thanks, Gigi. Good afternoon. Thank you for joining our conference call to discuss top line results from the Phase III PROPEL study of AT-GAA, Amicus' novel therapy for the treatment of late onset Pompe disease. Speaking on today's call, we have John Crowley, Chairman and Chief Executive Officer; Dr. Jeff Castelli, Chief Development Officer; and Dr. Mitch Goldman, Senior Vice President and Head of Clinical Research. Also joining for Q&A from Amicus are Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; and Dr. Hung do, Chief Science Officer.
As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private
Amicus Therapeutics Inc to Discuss the Topline PROPEL Results - Conference Call Transcript
Feb 12, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers